These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 14704596)

  • 1. Optimizing LDL-C lowering with statins.
    McKenney JM
    Am J Ther; 2004; 11(1):54-9. PubMed ID: 14704596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new reality: achieving cholesterol-lowering goals in clinical practice.
    Gaw A
    Atheroscler Suppl; 2002 Apr; 2(4):5-8; discussion 8-11. PubMed ID: 11976071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimization of cholesterol reduction principles and clinical results of dual inhibition].
    von Hodenberg E
    Internist (Berl); 2005 May; 46 Suppl 1():S18-23. PubMed ID: 15834540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of dyslipidemia.
    McKenney JM
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):413-22. PubMed ID: 11855660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of colesevelam in combination lipid-lowering therapy.
    Jones MR; Nwose OM
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):315-23. PubMed ID: 23913404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL
    Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving lipid management--to titrate, combine or switch.
    Schuster H
    Int J Clin Pract; 2004 Jul; 58(7):689-94. PubMed ID: 15311726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The power of statins: aggressive lipid lowering.
    Stein EA
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III25-31. PubMed ID: 12708636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL reduction: how low should we go and is it safe?
    Robinson JG
    Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.